Last reviewed · How we verify
NCT06211803: JPETClinic
Clinical Application of the Prototype J-PET Device
trial testing Positron-Emission Tomography Imaging in Neurodegenerative Diseases in 10 participants. Completed in 22 March 2022.
22 March 2022
Quick facts
| Lead sponsor | Jagiellonian University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 10 |
| Start date | 11 March 2022 |
| Primary completion | 22 March 2022 |
| Estimated completion | 22 March 2022 |
| Sites | 1 location across Poland |
Drugs / interventions tested
- Positron-Emission Tomography Imaging
Conditions studied
- Neurodegenerative Diseases — all drugs for Neurodegenerative Diseases →
- Brain Neoplasms — all drugs for Brain Neoplasms →
- Neuroendocrine Tumors — all drugs for Neuroendocrine Tumors →
Sponsor
Jagiellonian University
Who can join
Adults 18 to 80, any sex, with Neurodegenerative Diseases or Brain Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Positron emission tomography (PET) is a diagnostic imaging technique that uses positron emission (e-) to image changes in diagnosed tissues. Detector systems are an important part of PET scanners. They can convert gamma photons into fluorescent photons to obtain information about energy, time and position, of the gamma photons obtained through the use of an appropriate positron-emitting radiopharmaceutical. Conventional PET scanners are expensive mostly because they require the use of LSO (lutetium oxyorthosilicate) or LYSO (lutetium yttrium oxyorthosilicate) scintillation crystals. Such crystal scintillators are very costly and difficult to obtain, which limits accessibility of the PET- scanners. The prototype J-PET scanner tested in this trial uses plastic scintillators in which different physical phenomena occur compared to crystal scintillators. In addition, the J-PET scanner prototype is equipped with unique software enabling three-photon imaging, based on the annihilation resulting from the formation of the orto-positronium (o-Ps) in diagnosed tissue. The aim of this study is to demonstrate the clinical acceptability of such scanners based on plastic scintillators, which can additionally collect and process information on the lifetime of o-Ps derived from routinely used radiopharmaceuticals. Additionally, the aim of this study is to demonstrate the use of the new diagnostic indicator "positronium biomarker" in a prospective study, compared to routine diagnostic scanning.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06211803
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neurodegenerative Diseases
Currently open trials in the same condition.
- NCT07324330 — Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity · NA · recruiting
- NCT07268079 — Validation of the VIRADIA App for Neurological and Cognitive Diagnostics in Virtual Reality · recruiting
- NCT07514520 — Decision-making, Ethical Consent, and Interactive Dialogue in Ongoing Neurocognitive Decline - DECISION · active not recruiting
- NCT06755840 — Sleep Disordered Breathing and Multimorbidity: The Xiangya SDB Cohort Study · recruiting
- NCT06596746 — Neurodegenerative Diseases Progression Markers (MARKERS-NDD) · recruiting
Other Jagiellonian University trials
Trials by the same sponsor.
- NCT07410767 — Advanced Endoscopic Resections for Rectal Neoplasms · not yet recruiting
- NCT07364864 — Opioid-free Anesthesia as an Alternative to General Anesthesia in Patients Undergoing Duodenopancreatic Surgery by Lapar · NA · not yet recruiting
- NCT07378189 — Opioid-free Anesthesia as an Alternative to General Anesthesia in Patients Undergoing Laparoscopic Peripheral Pancreatic · NA · not yet recruiting
- NCT07389564 — Nationwide Registry of Patients With Heart Failure With Improved and Supranormal Ejection Fraction · active not recruiting
- NCT07306689 — Posttraumatic Stress Disorder in Ectopic Pregnancy · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06211803 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jagiellonian University
- Last refreshed: 18 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06211803.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing